Overview

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Status:
Recruiting
Trial end date:
2022-02-19
Target enrollment:
Participant gender:
Summary
Patients with low-risk MDS verifying the eligibility criteria may be included in the study.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Grenoble
Collaborator:
Novartis
Treatments:
Deferasirox